Bevacizumab for the Treatment of Recurrent Glioblastoma

Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the...

Full description

Bibliographic Details
Main Author:	Chamberlain, Marc C.
Format:	Online
Language:	English
Published:	Libertas Academica 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095028/

id	pubmed-3095028
recordtype	oai_dc
spelling	pubmed-30950282011-05-20 Bevacizumab for the Treatment of Recurrent Glioblastoma Chamberlain, Marc C. Review Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the dominant mediator of angiogenesis. A compelling biologic rationale, a need for improved therapy, and positive results from studies of bevacizumab in other cancers led to the evaluation of bevacizumab in the treatment of recurrent GBM. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has been shown to improve patient outcomes in combination with chemotherapy (most commonly irinotecan) in recurrent GBM, and on the basis of positive results in two prospective phase 2 studies, bevacizumab was granted accelerated approval by the US Food and Drug Administration (FDA) as a single agent in recurrent GBM. Bevacizumab therapy is associated with manageable, class-specific toxicity as severe treatment-related adverse events are observed in only a minority of patients. With the goal of addressing questions and controversies regarding the optimal use of bevacizumab, the objective of this review is to provide a summary of the clinical efficacy and safety data of bevacizumab in patients with recurrent GBM, the practical issues surrounding the administration of bevacizumab, and ongoing investigations of bevacizumab in managing GBM. Libertas Academica 2011-05-02 /pmc/articles/PMC3095028/ /pubmed/21603247 http://dx.doi.org/10.4137/CMO.S7232 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Chamberlain, Marc C.
spellingShingle	Chamberlain, Marc C. Bevacizumab for the Treatment of Recurrent Glioblastoma
author_facet	Chamberlain, Marc C.
author_sort	Chamberlain, Marc C.
title	Bevacizumab for the Treatment of Recurrent Glioblastoma
title_short	Bevacizumab for the Treatment of Recurrent Glioblastoma
title_full	Bevacizumab for the Treatment of Recurrent Glioblastoma
title_fullStr	Bevacizumab for the Treatment of Recurrent Glioblastoma
title_full_unstemmed	Bevacizumab for the Treatment of Recurrent Glioblastoma
title_sort	bevacizumab for the treatment of recurrent glioblastoma
description	Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the dominant mediator of angiogenesis. A compelling biologic rationale, a need for improved therapy, and positive results from studies of bevacizumab in other cancers led to the evaluation of bevacizumab in the treatment of recurrent GBM. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has been shown to improve patient outcomes in combination with chemotherapy (most commonly irinotecan) in recurrent GBM, and on the basis of positive results in two prospective phase 2 studies, bevacizumab was granted accelerated approval by the US Food and Drug Administration (FDA) as a single agent in recurrent GBM. Bevacizumab therapy is associated with manageable, class-specific toxicity as severe treatment-related adverse events are observed in only a minority of patients. With the goal of addressing questions and controversies regarding the optimal use of bevacizumab, the objective of this review is to provide a summary of the clinical efficacy and safety data of bevacizumab in patients with recurrent GBM, the practical issues surrounding the administration of bevacizumab, and ongoing investigations of bevacizumab in managing GBM.
publisher	Libertas Academica
publishDate	2011
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095028/
_version_	1611453875745718272

Bevacizumab for the Treatment of Recurrent Glioblastoma

Similar Items